Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.58 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14661779 | 0.90 | JAK2 (0.73) | JAK2CDC7 | |
| SCHEMBL14661733 | 0.85 | JAK2 (0.44) | JAK2JAK1TYK2 | |
| SCHEMBL14661630 | 0.81 | JAK2 (0.63) | JAK2CDC7 | |
| SCHEMBL14661641 | 0.78 | JAK2 (0.52) | JAK2JAK1TYK2 | |
| SCHEMBL15869794 | 0.76 | JAK2 (0.47) | JAK2AURKA | |
| SCHEMBL14661594 | 0.76 | JAK2 (0.50) | JAK2JAK1TYK2 | |
| SCHEMBL13730707 | 0.74 | JAK2 (1.00) | JAK2CDC7 | |
| SCHEMBL14661559 | 0.73 | JAK2 (0.47) | JAK2JAK1TYK2CDC7 | |
| SCHEMBL27282908 | 0.73 | JAK2 (0.42) | JAK2JAK1TYK2CDC7AURKB | |
| SCHEMBL13731177 | 0.73 | JAK2 (0.82) | JAK2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736514-B1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-10-18 | — | — | EP | disclosed |
| US-8912200-B2 | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-16 | — | — | US | disclosed |
| US-8912200-B2 | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-16 | — | — | US | disclosed |
| US-20140194406-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-10 | — | — | US | disclosed |
| US-20140194406-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194406-A1 | ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS | JAK2, JAK1, SRC | JAK2 1/4885JAK1 2/4885TYK2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.